Clinical Trials Browser

Phase 1 × Recruiting × Myasthenia Gravis × Clear all

NCT06680037 2026-05-18

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Phase 1 Recruiting

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Phase 1 Recruiting

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07085676 2026-05-06

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Phase 1 Recruiting

Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Scleroderma, Systemic, Antiphospholipid Syndrome, Multiple Sclerosis, Chronic Progressive

NCT07304154 2026-04-21

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Phase 1 Recruiting

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1 Recruiting

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT06220201 2026-02-10

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Phase 1 Recruiting

Multiple Sclerosis, Myasthenia Gravis

NCT07215650 2025-11-17

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Phase 1 Recruiting

Myasthenia Gravis

NCT06371040 2025-09-15

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

Phase 1 Recruiting

Myasthenia Gravis

NCT06688435 2025-08-06

A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

Phase 1 Recruiting

Myasthenia Gravis

NCT06249438 2025-07-25

CAR-AID

Phase 1 Recruiting

Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Scleroderma, Systemic

NCT06869278 2025-06-11

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Phase 1 Recruiting

Multiple Sclerosis, Myasthenia Gravis, Recurrence